Manufacturers report that odevixibat meets primary endpoint in phase 3 trial investigating use in progressive familial intrahepatic cholestasis

In the PEDFIC 1 phase 3 clinical trial, odevixibat, a highly potent, non-systemic ileal bile acid transport inhibitor, reduced serum bile acid responses (p=0.003) and improved pruritus assessments (p=0.004) vs placebo.


Biospace Inc.